Evidence map›Paper›PMID 21527828›Full record

ReviewCell cycle (Georgetown, Tex.)2011

FANCP/SLX4: a Swiss army knife of DNA interstrand crosslink repair.

Kelly E Cybulski, Niall G Howlett

Abstract readReview
In one paragraph

Review in Cell cycle (Georgetown, Tex.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kelly E CybulskiUniversity of Rhode Island, Kingston, RI, USA.
Niall G Howlett

Funding

Regulation of the Mono-Ubiquitination of the Fanconi Anemia D2 ProteinR01HL101977 · NHLBI · UNIVERSITY OF RHODE ISLAND · PI HOWLETT, NIALL GEORGE · 2011 to 2015
$1.3M
NHLBI NIH HHS R01 HL101977
6 · The paper itself

Abstract

Fanconi anemia (FA) is a rare genetic disease characterized by congenital abnormalities, bone marrow failure and heightened cancer susceptibility. The FA proteins are known to function in the cellular defense against DNA interstrand crosslinks (ICLs), a process that remains poorly understood. A recent spate of discoveries has led to the identification of one new FA gene, FANCP/SLX4, and two strong candidate FA genes, FAN1 and RAD51C. In this perspective we describe the discovery of FANCP/SLX4 and discuss how these new findings collectively refine our understanding of DNA ICL repair.

Indexed as

DNA RepairFanconi AnemiaFanconi Anemia Complementation Group ProteinsHumansRecombinasesFanconi Anemia Complementation Group ProteinsRecombinasesSLX4 protein, human

Identifiers

PMID21527828
PMCPMC3142459

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.